Atlas Trials

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Clinical trial NCT03008278 · COMPLETED

Trial details

NCT number
NCT03008278
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic Esophageal CarcinomaMetastatic Gastric CarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaRecurrent Esophageal CarcinomaRecurrent Gastric CarcinomaRecurrent Gastroesophageal Junction AdenocarcinomaStage III Esophageal Cancer AJCC v7Stage III Gastric Cancer AJCC v7Stage IV Esophageal Cancer AJCC v7Stage IV Gastric Cancer AJCC v7Unresectable Esophageal CarcinomaUnresectable Gastric Carcinoma
Start date
2018-02-06
Primary completion
2023-06-30
Enrollment
51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.